Kindred Biosciences, Inc.
KIN
KIN was delisted on the 27th of August, 2021.
83 hedge funds and large institutions have $118M invested in Kindred Biosciences, Inc. in 2020 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 36 increasing their positions, 16 reducing their positions, and 11 closing their positions.
53,300% more call options, than puts
Call options by funds: $534K | Put options by funds: $1K
125% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 16
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
11% more capital invested
Capital invested by funds: $106M → $118M (+$12M)
8% more funds holding
Funds holding: 77 → 83 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$3.77M |
| 2 |
Millennium Management
New York
|
+$3.67M |
| 3 |
Renaissance Technologies
New York
|
+$901K |
| 4 |
Wells Fargo
San Francisco,
California
|
+$602K |
| 5 |
HP
Hound Partners
New York
|
+$358K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$7.53M |
| 2 |
Allianz Asset Management
Munich,
Germany
|
-$1.34M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.16M |
| 4 |
AI
Ariel Investments
Chicago,
Illinois
|
-$1.08M |
| 5 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$515K |
KIN Hedge Fund Activity: Q2 2020 in Review
83 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Kindred Biosciences, Inc. (KIN) for Q2 2020, worth a combined $118M — up 11% from $106M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new KIN positions and 11 closed out — a net gain of 8 holders — while 36 added to existing stakes and 16 trimmed.
The largest buyer was Ameriprise, adding an estimated $3.77M. The largest seller was Morgan Stanley, cutting an estimated $7.53M.
- 83 institutional investors held Kindred Biosciences, Inc. (KIN) as of Q2 2020, up from 77 in Q1 2020.
- Funds reported $118M of Kindred Biosciences, Inc. stock for Q2 2020, up 11% quarter-over-quarter.
- 19 funds opened new Kindred Biosciences, Inc. positions in Q2 2020 and 11 closed out, a net change of +8 holders.
- The largest Kindred Biosciences, Inc. buyer in Q2 2020 was Ameriprise, an estimated $3.77M added.
- The largest Kindred Biosciences, Inc. seller in Q2 2020 was Morgan Stanley, an estimated $7.53M sold.
Based on aggregated 13F filings for Q2 2020.